EUFLEXXA(TM) received PMA approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit http://www.EUFLEXXA.com.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of orthopaedic products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Urology products include degarelix for prostate cancer (Phase III) and Minirin Melt for bladder dysfunction (Phase III).
Ferring also markets BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q.CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.
Other products include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.
The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.
1 Centers for Disease Control and Prevention. MMWR. 2004;53:388-389,
2 Kirchner M, Marshall D. A double-blind randomized controlled trial
comparing alternate forms of high molecular weight hyaluronan for the
treatment of osteoarthritis of the knee
|SOURCE Ferring Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved